Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy
MWN-AI** Summary
Tiziana Life Sciences, Inc. (Nasdaq: TLSA) has announced the successful dosing of the first patient in a Phase 2a clinical trial for its lead candidate, intranasal foralumab, aimed at treating Multiple System Atrophy (MSA). This trial, conducted at Brigham and Women’s Hospital in Boston, explores foralumab's potential to mitigate harmful neuroinflammation associated with this rare neurodegenerative disorder. MSA, classified as an orphan disease by the FDA, affects an estimated 15,000–50,000 individuals in the U.S. and currently lacks approved treatments that address its progressive nature.
This six-month open-label study (ClinicalTrials.gov Identifier: NCT06868628) evaluates the innovative delivery of foralumab through the intranasal route, targeting the brain's immune environment. The trial will involve eight dosing cycles, assessing whether this method can slow disease progression and enhance quality of life for patients facing this debilitating condition.
Dr. Vikram Khurana, Principal Investigator and Chief of Movement Disorders at Brigham and Women’s Hospital, expressed enthusiasm for the trial, emphasizing the urgent need for new treatment options for MSA patients. Tiziana's CEO, Ivor Elrifi, highlighted the company's mission to address the root causes of neurodegeneration rather than just alleviating symptoms. This trial is part of Tiziana’s broader research into foralumab, which has shown promise in stabilizing or improving function in other neurodegenerative conditions, such as multiple sclerosis.
Overall, the initiation of this trial marks a significant milestone for Tiziana Life Sciences as it seeks to innovate in the field of immunomodulation and provide new therapeutic options for MSA and other neurodegenerative diseases. For further details about Tiziana and its ongoing studies, visit their website at www.tizianalifesciences.com.
MWN-AI** Analysis
Tiziana Life Sciences (Nasdaq: TLSA) recently made headlines by enrolling the first patient in a Phase 2a clinical trial for its lead drug, intranasal foralumab, aimed at Multiple System Atrophy (MSA). As this rare and debilitating condition currently has no FDA-approved treatments capable of altering its progression, Tiziana's advancements could potentially unlock significant market opportunities.
Currently, Tiziana’s market position is bolstered by its unique approach with foralumab, a fully human anti-CD3 monoclonal antibody. This therapy is intriguing due to its novel intranasal delivery, which may effectively modulate immune responses while enhancing patient tolerability compared to traditional intravenous methods. As multiple studies affirm the efficacy of foralumab in stabilizing or improving functions in related neurodegenerative conditions, its potential success in the MSA indication could lead to substantial interest from investors and healthcare practitioners alike.
Given the urgency of treatment options for MSA patients, the market may react positively to milestones achieved in this clinical trial. Successful results could attract partnerships or increased funding, further enhancing Tiziana's research capabilities and leading to wider market applicability of their technology. However, investors should be mindful of the inherent risks associated with clinical trials, particularly in rare diseases where patient populations are small and outcomes are less predictable.
Strategically, investors might consider Tiziana Life Sciences as a speculative opportunity. Monitoring the trial's progression, along with broader market trends in the biotechnology sector, can provide insights into the timing for potential investments. Overall, while the landscape remains competitive, Tiziana’s innovative approach may position it favorably within the biopharmaceutical market.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
BOSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that the first participant has been enrolled and dosed in its Phase 2a clinical trial evaluating intranasal foralumab in patients living with Multiple System Atrophy (MSA) at Brigham and Women’s Hospital in Boston, Massachusetts.
MSA is a rare, rapidly progressive neurodegenerative disorder affecting the body’s movement, balance, and autonomic functions. Classified as an orphan disease by the FDA, MSA affects an estimated 15,000–50,000 people in the United States. There are no FDA-approved treatments that alter its course, creating a critical need for new therapeutic strategies.
The six-month open-label study (ClinicalTrials.gov Identifier: NCT06868628 ) will assess the potential of foralumab to reduce harmful neuroinflammation by engaging the body’s regulatory T cells through a novel, non-systemic delivery approach. Participants will receive treatment over eight dosing cycles, with the goal of determining whether this approach can slow disease progression and improve quality of life.
“We are excited to begin dosing nasal foralumab in MSA patients,” Said Dr. Vikram Khurana, MD, PhD, Tracy T. Batchelor Endowed Chair in Neurology, and Division Chief of Movement Disorders and Director of the MSA Center of Excellence at Brigham and Women’s Hospital and Principal Investigator of the MSA trial, commented: “Every patient I meet with MSA faces a reality of mounting symptoms and few options. This trial represents an important opportunity to explore a treatment aimed directly at the immune processes that may drive the disease. The intranasal route allows us to reach the brain’s immune environment in a way that is both targeted and potentially more tolerable for patients.”
Ivor Elrifi, Chief Executive Officer of Tiziana Life Sciences, added: “Our mission is to bring forward therapies that tackle the root causes of neurodegeneration, not just the symptoms. Dosing our first patient in this MSA study marks an important milestone in that mission. We are hopeful that foralumab’s unique mechanism – modulating immune response through the nasal pathway – can open new doors in treating diseases where inflammation and degeneration are intertwined.”
The trial builds on Tiziana’s broader research into foralumab in neuroinflammatory and neurodegenerative diseases, where early studies have suggested benefits in stabilizing or improving function in conditions such as multiple sclerosis.
About Multiple System Atrophy
Multiple System Atrophy is a rare and debilitating disorder involving the progressive loss of nerve cells in several areas of the brain. Symptoms may include severe problems with movement, balance, bladder control, and blood pressure regulation. The disease progresses quickly, and most patients survive only 6–9 years after diagnosis. No treatments are currently approved to slow or halt its progression.
About Foralumab
Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 10 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program ( NCT06802328 ) with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis ( NCT06292923 ).
Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. The non-active SPMS intranasal foralumab Phase 2 trial (NCT06292923) began screening patients in November of 2023. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases. [1],[2]
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com .
For further inquiries:
Tiziana Life Sciences Ltd
Paul Spencer, Business Development, and Investor Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com
[1] https://www.pnas.org/doi/10.1073/pnas.2220272120
[2] https://www.pnas.org/doi/10.1073/pnas.2309221120
FAQ**
How does Tiziana Life Sciences plc TLSA plan to leverage the results from the Phase 2a trial of intranasal foralumab to expand its product pipeline and address other neurodegenerative diseases in the future?
What specific metrics will Tiziana Life Sciences plc TLSA use to evaluate the effectiveness of intranasal foralumab in slowing MSA progression during the Phase clinical trial?
How does Tiziana Life Sciences plc TLSA anticipate the unique delivery mechanism of intranasal foralumab will impact patient compliance and overall treatment outcomes compared to traditional IV therapies?
What challenges does Tiziana Life Sciences plc TLSA foresee in advancing intranasal foralumab through regulatory approval, especially given the rarity of MSA and its classification as an orphan disease?
**MWN-AI FAQ is based on asking OpenAI questions about Tiziana Life Sciences plc (NASDAQ: TLSA).
NASDAQ: TLSA
TLSA Trading
-0.4% G/L:
$1.255 Last:
31,371 Volume:
$1.26 Open:
